PT-141 vs Setmelanotide
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, PT-141 or Setmelanotide?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between PT-141 and Setmelanotide?
PT-141 acts primarily on MC4R in the CNS for sexual arousal; setmelanotide acts on MC4R for energy homeostasis in patients with specific genetic lesions upstream - same receptor, different clinical applications, different patient populations.
Evidence Comparison
PT-141/bremelanotide (Vyleesi): FDA approved 2019 for HSDD in premenopausal women, Phase 3 data. Setmelanotide (Imcivree): FDA approved 2020 for rare genetic obesity (POMC/PCSK1/LEPR deficiency), Phase 3 data with dramatic weight loss in target population. Both have strong approval-quality evidence in their narrow indications.
Evidence Context Favoring PT-141
Hypoactive sexual desire disorder research in premenopausal women - PT-141 is the only approved melanocortin agonist for this indication.
Evidence Context Favoring Setmelanotide
Rare genetic obesity (POMC, PCSK1, or LEPR deficiency) where setmelanotide is the only targeted therapy with dramatic efficacy in genotype-confirmed patients.
Side-by-Side Snapshot
| Evidence grade | PT-141: Level A Setmelanotide: Level A |
|---|---|
| Research status | PT-141: FDA Approved Setmelanotide: FDA Approved |
| Primary category | PT-141: Sexual Health Setmelanotide: Weight Loss & Metabolic |
| Cited studies | PT-141: 2 Setmelanotide: 2 |